Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Leslie S L Kim"'
Autor:
Mariaelena Pierobon, Leslie S L Kim, Lance A. Liotta, Maren K Levin, Emanuel F. Petricoin, Elisa Baldelli, Joyce O'Shaughnessy
Publikováno v:
Cancer Research. 80:P4-10
Background: ER- HER2+ BC is comprised of a heterogeneous mix of intrinsic BC subtypes which have differential responsiveness to preop HER2-directed therapies combined with chemotherapy. Patients (pts) with ER- HER2+ BC whose disease progressed while
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b3ce35e3b99dcb3fb69385cd96e163df
https://doi.org/10.1158/1538-7445.sabcs19-p4-10-31
https://doi.org/10.1158/1538-7445.sabcs19-p4-10-31
Autor:
Dejan Juric, Therese M. Mulvey, Ioannis Sanidas, Hyo S. Han, Joyce O'Shaughnessy, Nikhil Wagle, Nicholas J. Dyson, Cynthia X. Ma, Irene Kuter, Siobhan Dunne, Laura Spring, Leslie S L Kim, Beverly Moy, Steven J. Isakoff, Mark L. Zangardi, Avinash Kambadakone, Andrzej Niemierko, Aditya Bardia, Veronica Mariotti, Apurva Pandey, Jing Xi, Azadeh Nasrazadani, Neelima Vidula, Kevin Kalinsky, Seth A. Wander, Megan Yuen, Adam Brufsky, Leif W. Ellisen, Casey Stein, Maxwell R. Lloyd
Publikováno v:
Journal of the National Comprehensive Cancer Network : JNCCN.
Background: Inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6i) are widely used as first-line therapy for hormone receptor–positive metastatic breast cancer (HR+ MBC). Although abemaciclib monotherapy is also FDA-approved for treatment of dise
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf6b8f4cdbdb36a6b3365eca30b145d1
https://pubmed.ncbi.nlm.nih.gov/33761455
https://pubmed.ncbi.nlm.nih.gov/33761455